Research Studies & Clinical Trials

Overview/Purpose

A5355 is a phase II, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of two injections of MVA Vaccine Encoding CMV antigens (Triplex®) in adults with both HIV and CMV. Participants will be randomized in a 2:1 ratio to receive either two injections of CMV-MVA Triplex® or placebo administered at study Entry/Day 0 and week 4. Participants will have follow-up visits in person or by phone for 92 weeks after the second injection, for a total of 96 weeks of follow-up. During the study, participants will have blood, urine, genital secretions, and oral secretions collected.

Interested in Volunteering?

CMV infection is common in people living with HIV and often silent, but causes chronic inflammation. This study is testing an investigational vaccine that targets CMV called Triplex®.

Basic Eligibility Criteria:

• Age: 18-65 years old
• Living with HIV and positive for CMV (study will do the test for CMV)
• On continuous HIV treatment for at least 48 weeks
• CD4 count > 250

Principal Investigator:

Kara Chew, MD, MS

For more information, please contact the UCLA CARE Center:

[email protected]
310-843-2015

If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.

 

Additional Resources:

Study Flyer

https://clinicaltrials.gov/ct2/show/NCT05099965